Cemiplimab
- Generic Name
- Cemiplimab
- Brand Names
- Libtayo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1801342-60-8
- Unique Ingredient Identifier
- 6QVL057INT
- Background
Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
...
- Indication
Cemiplimab is indicated to treat:
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic cutaneous squamous cell carcinoma, Recurrent Cervical Cancer, Metastatic Basal cell carcinoma
- Associated Therapies
- First Line Chemotherapy
Cemiplimab for Secondary Angiosarcomas
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT04873375
- Locations
- 🇳🇱
RadboudUMC, Nijmegen, Netherlands
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell CarcinomaMetastatic Oral Cavity Squamous Cell CarcinomaMetastatic Oropharyngeal Squamous Cell CarcinomaPathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Marcelo Bonomi
- Target Recruit Count
- 52
- Registration Number
- NCT04862650
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- University of Miami
- Registration Number
- NCT04831450
ASP8374 + Cemiplimab in Recurrent Glioma
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT04826393
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Won Seog Kim
- Target Recruit Count
- 37
- Registration Number
- NCT04763616
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Kangnamgu, Korea, Republic of
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04722523
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
LAG3 PET Imaging in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 41
- Registration Number
- NCT04706715
- Locations
- 🇳🇱
University Medical Center Groninen, Groningen, Netherlands
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 113
- Registration Number
- NCT04646005
- Locations
- 🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇧🇪Universitair Ziekenhuis Gent, Gent, East Flanders, Belgium
🇧🇪CHIREC Delta Hospital / Chirec Cancer Institute, Brussels, Belgium
Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Fondazione Melanoma Onlus
- Target Recruit Count
- 25
- Registration Number
- NCT04632433
- Locations
- 🇮🇹
Ospedale S.M. Annunziata - Azienda USL Toscana Centro, Bagno A Ripoli, Firenze, Italy
🇮🇹ASST Spedali Civili Brescia, Brescia, Italy
🇮🇹Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale", Naples, Italy
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 769
- Registration Number
- NCT04626635
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸University of Florida Health, Gainesville, Florida, United States
🇹🇷Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.